HCPCS code J9302: Ofatumumab injection, per 10 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9302 covers

J9302 represents ofatumumab, an anti-CD20 monoclonal antibody used in oncology treatment of chronic lymphocytic leukemia (CLL). The oncology formulation is administered by intravenous infusion, typically by clinical staff in a hospital outpatient department or physician office. This is the drug code; it identifies the medication supplied and administered, rather than the infusion service.

CMS assigns J9302 physician fee schedule status E, excluding it from the physician fee schedule. When Medicare covers the drug, payment is under another method; HCPCS pricing identifies it as a Part B drug, generally priced from CMS quarterly Average Sales Price files. Coverage is left to the Medicare contractor’s judgment. One billing unit represents 10 mg of ofatumumab, so the administered dose in milligrams is divided by 10 to determine the units reported.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9302 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9302 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9302 rate is calculated

Each of J9302’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9302

J9302 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9302 compared with similar codes

How to choose

J9301ObinutuzumabPer 10 mg

J9301 identifies obinutuzumab, not ofatumumab. Both are anti-CD20 drugs used in CLL care, so select the code for the medication actually administered.

J9312Rituximab injectionPer 10 mg

J9312 identifies rituximab, whereas J9302 identifies ofatumumab. They are different drugs even when used for related hematologic treatment needs.

Codes related to J9302

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates